Ustekinumab sub cu inj, 1 mg
This code is not in the latest file (4Q26). It was last listed in 1Q25.
Payment limit per 1 MG, by effective quarter, 1Q21 to 1Q25. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.This code is not in the latest file (4Q26). It was last listed in 1Q25.
Payment limit per 1 MG, by effective quarter, 1Q21 to 1Q25. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.No NDCs mapped to this code in the 4Q26 crosswalk.
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 1Q25 | $155.883 | −$4.03 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $159.913 | +$1.755 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $158.158 | +$5.593 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $152.565 | −$1.39 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $153.955 | +$2.497 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $151.458 | +$3.811 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $147.647 | −$6.121 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $153.768 | −$1.234 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $155.002 | −$7.847 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $162.849 | −$11.842 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $174.691 | +$8.376 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $166.315 | −$4.504 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $170.819 | −$5.95 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $176.769 | +$4.30 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $172.469 | +$1.291 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $171.178 | −$8.938 | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $180.116 | – | 1 MG | Ustekinumab sub cu inj, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.